Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Credit agrmnt [a]
Appointed CFO
Quarterly results
Director departure
CC transcript

Anika Therapeutics, Inc. (ANIK) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 4 Nunes Anne (SVP, Chief Operations Officer) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Paid exercise price by delivering 732 shares @ $18.63, valued at $13.6k
Exercised 2,491 restricted stock units @ $0
08/17/2023 SC 13D Caligan Partners LP reports a 6.2% stake in Anika Therapeutics, Inc.
08/11/2023 4 Levitz Michael L (EVP, CFO, Treasurer) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Paid exercise price by delivering 1,133 shares @ $18.58, valued at $21.1k
Exercised 3,859 restricted stock units @ $0
08/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Anika Reports Second Quarter 2023 Financial Results"
06/16/2023 4 VOGT SUSAN L N (Director) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Granted 6,500 shares @ $0
06/16/2023 4 Thompson Jeffery S (Director) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Granted 6,500 shares @ $0
06/16/2023 4 Richard Stephen (Director) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Granted 6,500 shares @ $0
06/16/2023 4 Larsen Glenn R. (Director) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Granted 6,500 shares @ $0
06/16/2023 4 HENNEMAN JOHN B III (Director) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Granted 6,500 shares @ $0
06/16/2023 4 Fischetti Gary P (Director) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Granted 6,500 shares @ $0
06/16/2023 4 CONLEY SHERYL L (Director) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Granted 6,500 shares @ $0
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Anika Reports First Quarter 2023 Financial Results Positive Start to 2023 Revenue Growth with OA Pain Management Up 8% and Joint Preservation and Restoration Up 11%"
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/28/2023 4 Blanchard Cheryl R (President, CEO, Director) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Paid exercise price by delivering 10,900 shares @ $26.34, valued at $287.1k
Exercised 24,575 restricted stock units @ $0
04/28/2023 8-K Quarterly results
04/25/2023 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
04/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/17/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/13/2023 8-K Quarterly results
04/05/2023 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
03/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/27/2023 PREC14A Form PREC14A - Preliminary proxy statements, contested solicitations:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/14/2023 4 Levitz Michael L (EVP, CFO, Treasurer) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Paid exercise price by delivering 2,609 shares @ $26.1, valued at $68.1k
Exercised 8,888 restricted stock units @ $0
03/14/2023 4 Colleran David (EVP, General Counsel, Corp Sec) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Paid exercise price by delivering 2,250 shares @ $26.1, valued at $58.7k
Exercised 7,663 restricted stock units @ $0
03/14/2023 4 Blanchard Cheryl R (President, CEO, Director) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Paid exercise price by delivering 13,211 shares @ $26.1, valued at $344.8k
Exercised 30,060 restricted stock units @ $0
03/10/2023 4 Levitz Michael L (EVP, CFO, Treasurer) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Paid exercise price by delivering 1,303 shares @ $26.91, valued at $35.1k
Granted 17,624 restricted stock units @ $0
Granted 38,475 options to buy @ $0
Exercised 4,439 restricted stock units @ $0
03/10/2023 4 Colleran David (EVP, General Counsel, Corp Sec) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Paid exercise price by delivering 1,081 shares @ $26.91, valued at $29.1k
Granted 16,395 restricted stock units @ $0
Granted 35,790 options to buy @ $0
Exercised 3,683 restricted stock units @ $0
03/10/2023 4 Blanchard Cheryl R (President, CEO, Director) has filed a Form 4 on Anika Therapeutics, Inc.
Txns: Paid exercise price by delivering 4,232 shares @ $26.91, valued at $113.9k
Granted 60,004 restricted stock units @ $0
Granted 130,998 options to buy @ $0
Exercised 14,419 restricted stock units @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy